| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OPK Stock Overview
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
OPKO Health Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$5.25 |
| 52 Week Low | US$2.18 |
| Beta | 1.88 |
| 1 Month Change | -17.50% |
| 3 Month Change | -26.26% |
| 1 Year Change | -31.61% |
| 3 Year Change | 8.20% |
| 5 Year Change | -59.88% |
| Change since IPO | -41.33% |
Recent News & Updates
OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Company misses earnings and sales targets in Q1. New deals abound but the market goes unnoticed. High costs and declining margins continue to put pressure on the bottom-line.
Shareholder Returns
| OPK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 9.1% | 7.8% | 6.6% |
| 1Y | -31.6% | 2.5% | -18.4% |
Return vs Industry: OPK underperformed the US Healthcare industry which returned 2.4% over the past year.
Return vs Market: OPK underperformed the US Market which returned -18.4% over the past year.
Price Volatility
| OPK volatility | |
|---|---|
| OPK Average Weekly Movement | 11.4% |
| Healthcare Industry Average Movement | 9.5% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: OPK's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 5,767 | Phil Frost | https://www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins.
OPKO Health Fundamentals Summary
| OPK fundamental statistics | |
|---|---|
| Market Cap | US$1.80b |
| Earnings (TTM) | -US$116.65m |
| Revenue (TTM) | US$1.56b |
1.2x
P/S Ratio-15.4x
P/E RatioIs OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPK income statement (TTM) | |
|---|---|
| Revenue | US$1.56b |
| Cost of Revenue | US$1.15b |
| Gross Profit | US$409.36m |
| Other Expenses | US$526.02m |
| Earnings | -US$116.65m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 26.26% |
| Net Profit Margin | -7.48% |
| Debt/Equity Ratio | 14.2% |
How did OPK perform over the long term?
See historical performance and comparisonValuation
Is OPK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPK?
Other financial metrics that can be useful for relative valuation.
| What is OPK's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$1.80b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | -62.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OPK's PS Ratio compare to its peers?
| OPK PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
AMEH Apollo Medical Holdings | 2.1x | n/a | US$1.8b |
ONEM 1Life Healthcare | 2.3x | 22.2% | US$1.8b |
ADUS Addus HomeCare | 1.5x | 7.3% | US$1.4b |
MODV ModivCare | 0.6x | 8.3% | US$1.3b |
OPK OPKO Health | 1.2x | 2.5% | US$1.8b |
Price-To-Sales vs Peers: OPK is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (1.6x).
Price to Earnings Ratio vs Industry
How does OPK's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: OPK is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Healthcare industry average (1.4x)
Price to Sales Ratio vs Fair Ratio
What is OPK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 1.1x |
Price-To-Sales vs Fair Ratio: OPK is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Share Price vs Fair Value
What is the Fair Price of OPK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPK ($2.64) is trading above our estimate of fair value ($0.01)
Significantly Below Fair Value: OPK is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPK's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
66.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OPK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OPK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OPK's revenue (2.5% per year) is forecast to grow slower than the US market (8.4% per year).
High Growth Revenue: OPK's revenue (2.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has OPKO Health performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
24.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPK is currently unprofitable.
Growing Profit Margin: OPK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPK is unprofitable, but has reduced losses over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare OPK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.8%).
Return on Equity
High ROE: OPK has a negative Return on Equity (-7.22%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is OPKO Health's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OPK's short term assets ($754.1M) exceed its short term liabilities ($309.2M).
Long Term Liabilities: OPK's short term assets ($754.1M) exceed its long term liabilities ($382.8M).
Debt to Equity History and Analysis
Debt Level: OPK's net debt to equity ratio (7.9%) is considered satisfactory.
Reducing Debt: OPK's debt to equity ratio has increased from 4.4% to 14.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OPK has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 11.9% each year.
Discover healthy companies
Dividend
What is OPKO Health current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OPK has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
8.3yrs
Average management tenure
CEO
Phil Frost (85 yo)
15.25yrs
Tenure
US$2,103,600
Compensation
Dr. Phillip Frost, also known as Phil, M.D., Ph D., has been the Chairman, Chief Executive Officer and Director of OPKO Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and Gene...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD2.10M) is below average for companies of similar size in the US market ($USD5.47M).
Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: OPK's management team is seasoned and experienced (8.3 years average tenure).
Board Members
Experienced Board: OPK's board of directors are seasoned and experienced ( 14.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
OPKO Health, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: OPKO Health, Inc.
- Ticker: OPK
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.800b
- Shares outstanding: 681.95m
- Website: https://www.opko.com
Number of Employees
Location
- OPKO Health, Inc.
- 4400 Biscayne Boulevard
- Miami
- Florida
- 33137
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/26 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.